Development of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ)

Matza, Louis S.; Boye, Kristina S.; Stewart, Katie D.; Paczkowski, Rosirene; Jordan, Jessica; Murray, Lindsey T.

doi:10.1186/s41687-018-0068-z

Journal of Patient-Reported Outcomes

Table 1 Participant Characteristics (Concept Elicitation)

From: Development of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ)

Characteristic	US	UK	Germany	Total Sample^a
N	11	14	7	32
Mean Age (years) (SD)	56.91 (11.4)	59.57 (14.0)	67.43 (5.4)	60.38 (12.0)
Gender
Female	7 (63.6%)	6 (42.9%)	3 (42.9%)	16 (50.0%)
Male	4 (36.4%)	8 (57.1%)	4 (57.1)	16 (50.0%)
Ethnic/Racial Background (n, %)
White	4 (36.4%)	12 (85.7%)	7 (100.0%)	23 (71.9%)
Mixed	1 (9.1%)	0 (0.0%)	0 (0.0%)	1 (3.1%)
Asian	1 (9.1%)	0 (0.0%)	0 (0.0%)	1 (3.1%)
Black	4 (36.4%)	2 (14.3%)	0 (0.0%)	6 (18.8%)
Other^b	1 (9.1%)	0 (0.0%)	0 (0.0%)	1 (3.1%)
Marital Status (n, %)
Single	1 (9.1%)	4 (28.6%)	0 (0.0%)	5 (15.6%)
Married/Living with partner	6 (54.5%)	7 (50.0%)	4 (57.1%)	17 (53.1%)
Other^c	4 (36.4%)	3 (21.4%)	3 (42.9%)	10 (31.3%)
Employment Status (n, %)^d
Full-time work	5 (45.5%)	2 (14.3%)	1 (14.3%)	8 (25.0%)
Part-time work	1 (9.1%)	2 (14.3%)	0 (0.0%)	3 (9.4%)
Other^e	5 (45.5%)	10 (71.4%)	6 (85.7%)	21 (65.6%)
Education Level (n, %)
University degree	5 (45.5%)	3 (21.4%)	2 (28.6%)	10 (31.3%)
No University degree	6 (54.5%)	11 (78.6%)	5 (71.4%)	22 (68.7%)
Interview Type
In-Person (n)	1 (9.1%)	14 (100.0%)	1 (14.3%)	16 (50.0%)
Telephone (n)	10 (90.9%)	0 (0.0%)	6 (85.7%)	16 (50.0%)
Medication History
Current GLP-1	7 (63.6%)	11 (78.6%)	7 (100.0%)	25 (78.1%)
Discontinued GLP-1	0 (0.0%)	2 (14.3%)	0 (0.0%)	2 (6.3%)
Current GLP-1 and Insulin	4 (36.4%)	1 (7.1%)	0 (0.0%)	5 (15.6%)
Current GLP-1 RAs
Liraglutide	3 (27.3%)	3 (21.4%)	4 (57.1%)	10 (31.3%)
Exenatide twice daily	0 (0.0%)	4 (28.6%)	1 (14.3%)	5 (15.6%)
Exenatide extended release tray	1 (9.1%)	1 (7.1%)	2 (28.6%)	4 (12.5%)
Lixisenatide	0 (0.0%)	4 (28.6%)	0 (0.0%)	4 (12.5%)
Exenatide extended release pen	3 (27.3%)	0 (0.0%)	0 (0.0%)	3 (9.4%)
Dulaglutide	2 (18.2%)	0 (0.0%)	0 (0.0%)	2 (6.3%)
Albiglutide	2 (18.2%)	0 (0.0%)	0 (0.0%)	2 (6.3%)
Discontinued GLP-1 RAs^f
Liraglutide	1 (9.1%)	1 (7.1%)	0 (0.0%)	2 (6.3%)
Exenatide extended release pen	1 (9.1%)	1 (7.1%)	0 (0.0%)	2 (6.3%)

^aThis table includes data for the 32 participants who provided proof of medication, were eligible, and completed a satisfactory interview according to the interview guide. Two additional participants were enrolled in the study but excluded from the analysis sample because of deviations from the interview guide
^bOther ethnic/racial background includes: Hispanic (total: n = 1; US: n = 1)
^cOther marital status includes: Divorced (total: n = 7; US: n = 4; Germany: n = 3); Separated (total: n = 2; UK: n = 2), Widowed (total: n = 1; UK: n = 1)
^dPercentages for employment status in the US sum to 100.1% due to rounding
^eOther employment status includes: US: Retired (n = 3), Retired and disabled (n = 2); UK: Retired (n = 9), Homemaker (n = 1); Germany: Retired (n = 5), Retired and disabled (n = 1)
^fGLP-1 RAs discontinued within the past 6 months. No patients reported discontinuing any GLP-1 RAs other than liraglutide and exenatide once weekly

Back to article page